GQ Features Motivant’s Sanjiv Lal on Peptide Regulation Changes
GQ recently published a deep dive into the potential recategorization of over a dozen previously banned peptides, following Health Secretary Robert F. Kennedy Jr.’s announcement that the FDA will be loosening regulations on compounds previously placed on the agency’s category 2 list. Motivant Co-Founder and Partner Sanjiv Lal was featured as an expert source in the article, offering perspective on the regulatory landscape and what it means for patients and providers.
The Regulatory Shift
The FDA’s category 2 list effectively banned compounding pharmacies from formulating certain peptides for human use, restricting doctors from prescribing them. According to Kennedy, approximately 14 of these peptides are expected to be moved back to category 1, where they become available for pharmacy compounding and physician-prescribed treatment. The move would reverse decisions made under the previous administration that many in the industry viewed as regulatory overreach.
As Sanjiv noted in the article: “The debate isn’t about whether peptides work. It’s about which ones have enough evidence and regulatory oversight around them.”
Why This Matters
The potential recategorization has significant implications across the longevity and regenerative wellness space. Patients who previously relied on these peptides for conditions related to inflammation, gut health, metabolism, and cognition were forced to either discontinue treatment or seek alternatives through unregulated channels when the ban took effect. A return to category 1 would restore access through FDA-inspected facilities and physician-guided care.
Perhaps more importantly, recategorization would open the door to more rigorous research. The category 2 designation drastically restricted the types of studies that could be conducted on these compounds. Moving them back to category 1 creates incentive for pharmaceutical companies and researchers to investigate efficacy and safety more thoroughly.
Motivant’s Position in the Longevity Space
Sanjiv’s inclusion as an expert source in GQ reflects Motivant’s growing authority in the regenerative wellness and longevity category. With 24 years of experience in pharmaceuticals, biotechnology, and molecular genetics, Sanjiv brings deep expertise in anticipating market trends and navigating the evolving healthcare landscape. His perspective on peptide regulation draws from both scientific understanding and operational experience scaling laboratories and bringing transformative products to market.
Through our investment in Beverly Hills Rejuvenation Center, Motivant has positioned itself at the intersection of clinical innovation and consumer wellness. BHRC’s integration of Cell Factor (Quantum), a next-generation regenerative platform, exemplifies the kind of protocol-driven, physician-guided approach that responsible peptide and regenerative therapy delivery requires. As regulatory frameworks evolve, brands with established clinical infrastructure and provider networks will be best positioned to serve patients safely and effectively.
Looking Ahead
The peptide landscape is shifting rapidly. Whether you view the potential recategorization as a course correction or a starting point for needed research, the trajectory is clear: demand for these compounds continues to grow, and the market will benefit from moving treatment out of gray channels and into regulated, transparent settings. National media coverage like this GQ feature signals mainstream recognition of the category’s significance and the expertise required to navigate it responsibly.
We exist to influence, inspire, and ignite people to transform together. Our work in the longevity and regenerative wellness space embodies that mission.
Read the Full Article:
GQ: It’s About to Be Hot Peptide Summer
About Sanjiv Lal
Sanjiv Lal is Co-Founder and Partner at Motivant, where he oversees business development and sales. With 24 years of experience in pharmaceuticals, biotechnology, and molecular genetics, he has successfully founded and scaled multiple laboratories. Sanjiv also serves as Chief Innovation Officer at Beverly Hills Rejuvenation Center. He holds a Bachelor of Science and Master of Science in Pharmaceutical Sciences from The Ohio State University.
About Beverly Hills Rejuvenation Center
Founded in 2005, Beverly Hills Rejuvenation Center is a nationally recognized brand and leader in the longevity, regenerative wellness and beauty industries. Rooted in science, empowered by innovation, and fueled by purpose, BHRC is pioneering proprietary aesthetic treatments and personalized health optimization with 22+ centers across the United States.
Learn more: bhrcenter.com
About Motivant
Motivant is an entrepreneur-led family office with operational expertise in the areas of healthcare, life sciences, real estate, and hospitality. Our team of seasoned business leaders brings a diverse range of entrepreneurial expertise, united by a commitment to excellence and a focus on creating and delivering meaningful value.
Learn more: bemotivant.com